Sarcoma
Welcome,         Profile    Billing    Logout  
 515 Companies   302 Products   302 Products   167 Mechanisms of Action   1404 Trials   125634 News 


«12...14901491149214931494149514961497149814991500...15771578»
  • ||||||||||  Journal:  Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. (Pubmed Central) -  Nov 30, 2017   
    This presents an opportunity to develop miR-181c and NOTCH2 as markers for early identification of high risk cases and the use of NOTCH inhibitors in the prevention or treatment of recurrent disease. Our study suggests that taxane/platinum doublet may be a more effective chemotherapy regimen compared to other regimens among women with recurrent uterine carcinosarcoma, especially for those who had a disease-free interval of ≥6months.
  • ||||||||||  Review, Journal:  Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future. (Pubmed Central) -  Nov 30, 2017   
    Key recommendations included the: 1) development of standardized, cost-efficient fluorodeoxyglucose positron emission tomography and whole-body magnetic resonance imaging guidelines to evaluate masses concerning for MPNST; 2) development of better understanding and histologic criteria for the transformation of a plexiform neurofibroma to MPNST; 3) establishment of a centralized database to collect genetic, genomic, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from MPNST subspecialty centers in a standardized manner; 4) creation of accurate mouse models to study the plexiform neurofibroma-to-MPNST transition, MPNST metastasis, and drug resistance; 5) use of trial designs that minimize regulatory requirements, maximize availability to patients, consider novel secondary end points, and study patients with newly diagnosed disease. Lastly, in order to minimize delays in developing novel therapies and promote the most efficient use of research resources and patient samples, data sharing should be incentivized.
  • ||||||||||  Trial withdrawal:  A Vaccine Study for High Risk Cancers (clinicaltrials.gov) -  Nov 24, 2017   
    P1,  N=0, Withdrawn, 
    Suspended --> Active, not recruiting | N=360 --> 28 Terminated --> Withdrawn
  • ||||||||||  Enrollment change, Trial primary completion date, HEOR:  A Survivorship Care Plan for Gynaecological Cancer Patients (clinicaltrials.gov) -  Nov 24, 2017   
    P=N/A,  N=150, Completed, 
    Terminated --> Withdrawn N=75 --> 150 | Trial primary completion date: Aug 2013 --> Mar 2014
  • ||||||||||  temozolomide / Generic mfg.
    Phase classification, Trial primary completion date:  Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  Nov 22, 2017   
    P1,  N=21, Active, not recruiting, 
    Our collective results demonstrate that Reolysin possesses CXCL10-driven anti-angiogenic activity in sarcoma models, which can be harnessed to enhance the anticancer activity of temsirolimus and other agents that target the tumor vasculature. Phase classification: P=N/A --> P1 | Trial primary completion date: Nov 2017 --> Feb 2017
  • ||||||||||  Biomarker, Journal:  CD49b inhibits osteogenic differentiation and plays an important role in osteosarcoma progression. (Pubmed Central) -  Nov 21, 2017   
    CD49b expression in osteosarcoma patients was associated with presence of metastases and inferior 5 year overall survival (31.4% vs. 57.4%, p=0.03). Surface proteins involved in osteosarcoma cell differentiation, such as CD49b, have the potential to serve as prognostic biomarkers, and may lead to the identification of new therapeutic targets.
  • ||||||||||  samrotamab vedotin (ABBV-085) / AbbVie
    Trial primary completion date, Metastases:  ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Nov 17, 2017   
    P1,  N=220, Recruiting, 
    Recruiting --> Completed | Trial primary completion date: Dec 2018 --> Nov 2017 Trial primary completion date: Dec 2018 --> Jun 2018
  • ||||||||||  cisplatin / Generic mfg., acetylcysteine solution / Generic mfg.
    Trial primary completion date:  NAC to Prevent Cisplatin-induced Hearing Loss (clinicaltrials.gov) -  Nov 14, 2017   
    P1,  N=30, Recruiting, 
    Trial primary completion date: Dec 2017 --> Jun 2018 Trial primary completion date: Feb 2018 --> Feb 2019
  • ||||||||||  Votrient (pazopanib) / Novartis
    Enrollment change, Trial initiation date, Trial termination, Trial primary completion date:  Pazopanib Maintenance Phase II (clinicaltrials.gov) -  Nov 13, 2017   
    P2,  N=1, Terminated, 
    N=48 --> 18 N=150 --> 1 | Initiation date: Dec 2014 --> Jun 2015 | Recruiting --> Terminated | Trial primary completion date: Jun 2017 --> Jul 2016; poor recruitment
  • ||||||||||  Journal:  From vision to reality: deploying the immune system for treatment of sarcoma. (Pubmed Central) -  Nov 10, 2017   
    We review the available literature regarding the immune microenvironment in sarcomas, with emphasis on tumor evasion mechanisms that can be targeted with immunotherapeutic strategies. We also highlight recent clinical trials of immunotherapy that show exciting signals of activity in refractory sarcomas.
  • ||||||||||  Journal:  Inhibition of porcupine prolongs metastasis free survival in a mouse xenograft model of Ewing sarcoma. (Pubmed Central) -  Nov 9, 2017   
    The drug produces no survival benefit in a tail vein injection model, supporting the hypothesis that WNT974 inhibits early steps in the metastatic cascade, such as migration and invasion. Our findings strongly implicate Wnt signaling in the early steps of ES metastasis and demonstrate that WNT974 has the potential to significantly improve the survival of ES patients through the specific inhibition of metastasis.
  • ||||||||||  Journal:  Size-based detection of sarcoma circulating tumor cells and cell clusters. (Pubmed Central) -  Nov 9, 2017   
    Although evaluation of CTC is established in the care of patients with carcinomas, this technology has yet to be effectively applied to the evaluation and treatment of sarcoma patients. Our work demonstrates that the CellSieve™ microfiltration system can be used to study the biology of CTC in both mouse models and human sarcoma patients, with the potential for application to the monitoring of disease response and prediction of metastatic relapse.
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Trial primary completion date, Stroma:  Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan). (clinicaltrials.gov) -  Nov 9, 2017   
    P=N/A,  N=472, Completed, 
    Our work demonstrates that the CellSieve™ microfiltration system can be used to study the biology of CTC in both mouse models and human sarcoma patients, with the potential for application to the monitoring of disease response and prediction of metastatic relapse. Trial primary completion date: May 2013 --> Oct 2015
  • ||||||||||  ESP-01 / Esperas
    Trial primary completion date, Combination therapy, Monotherapy, Metastases:  A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov) -  Nov 8, 2017   
    P1b/2a,  N=93, Recruiting, 
    Trial primary completion date: Oct 2017 --> Oct 2019 Trial primary completion date: Nov 2017 --> Mar 2018
  • ||||||||||  Journal:  Characterization of 298 lung cancer patients harboring MET exon 14 skipping (METex14) alterations. (Pubmed Central) -  Nov 8, 2017   
    Diverse targetable METex14 alterations were identified in patients with NSCLC across age groups, including elderly patients, and in all major NSCLC histologic subtypes with an overall frequency of 2.7%. These findings support the use of hybrid capture-based molecular profiling across NSCLC subtypes to identify patients who will potentially benefit from MET TKIs.
  • ||||||||||  Biomarker, New trial:  Epigenetic Biomarker for Osteosarcoma (clinicaltrials.gov) -  Nov 8, 2017   
    P=N/A,  N=100, Recruiting, 
  • ||||||||||  Votrient (pazopanib) / Novartis
    Trial primary completion date, Combination therapy:  Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma (clinicaltrials.gov) -  Nov 7, 2017   
    P2,  N=80, Recruiting, 
    These findings support the use of hybrid capture-based molecular profiling across NSCLC subtypes to identify patients who will potentially benefit from MET TKIs. Trial primary completion date: Mar 2018 --> Mar 2019